The most advanced technological bioprinting laboratory will open in 2017 in Cyprus.
A new project in collaboration of NextGene Biosystem (Blagoveshchensk, Russia), Amur State Medical Academy (Amur region, Russia) and IQDEMY SA Holding (IQJET ARTISIA Company is a part of the Holding, Switzerland) will see Cyprus to be put on the global map for bioprinting, it is announced today.
Cyprus State University and IQJET ARTISIA Company plan to open the most advanced bioprinting laboratory on the island next year. Together with the leaders in the field of tissue engineering (cell engineering) and health care in Russia, NextGene Biosystem and Amur State Medical Academy, research activity is aimed at the development of disease treatment based on 3D printing (bioprinting) for structural cell changes.
Bioprinting as well as 3D printing are promising fields of research for solutions for bio-cellular printing will undoubtedly advance medical science and implantology. This is one of the reasons why the bioprinting industry gets popular among scientists and potential investors thus being a topic that is raised and discussed with ever increasing frequency by scientific communities.
The project results from long-term collaboration between IQDEMY SA and NextGene which carried out joint research at IQDEMY CHEMISTRY’s labs in Novosibirsk Akademgorodok. Here, at the fondly called “Silicon Forest” companies from the IT, pharmaceutical, metallurgy and fossil fuels industries, are located.
Development of an innovative bioprinter, that creates a kind of artificial skin for patients with skin burns and scalds as well as tropical ulcer, is currently carried out by IQ ARTISIA and NextGeneBiosystem.
The expertise of IQDEMY CHEMISTRY, represents, among others, research of material rheological properties, bio-ink and bioprinter engineering, meeting both biotechnology and digital printing requirements, in which the company is very successful.
Last August, at the Biointerfaces International Conference (BIC), one of the significant events of this industry, in Switzerland, Doctor Güttinger inspired both research companies. He specified the requirement for a bioprinting laboratory in Europe that would cater to global demands for such technology.
This statement resulted in ARTISIA IQJet company and the University of Cyprus exploring possible cooperation on the subject of bioprinting. A series of meetings between Vladislav Mirchev (IQDEMY SA President), Olga Kondratieva (IQDEMY SA Development Director) and the Head of the University of Cyprus as well as KPMG Company, represented by Mr. Angelos M Gregoriades (KPMG Cyprus Chairman) and Mr. Tassos Yiasemides (KPMG Cyprus Board Member), as organizer followed. The companies’ representatives discussed possibilities for joint investment in a bioprinting laboratory project. Artisia IQJet and University of Cyprus decided to start the scientific project for bioprinting industry research and development.
The project initiators are convinced, that joint research a the new bioprinting laboratory by NextGene Biosystem, Amur State Medical Academy and IQDEMY Chemistry as well as European Scientists will help to achieve scientific breakthroughs in bioprinting.